<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d2 20140930//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.0 20040830//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">Allergy</journal-id><journal-id journal-id-type="iso-abbrev">Allergy</journal-id><journal-id journal-id-type="publisher-id">all</journal-id><journal-title-group><journal-title>Allergy</journal-title></journal-title-group><issn pub-type="ppub">0105-4538</issn><issn pub-type="epub">1398-9995</issn><publisher><publisher-name>BlackWell Publishing Ltd</publisher-name><publisher-loc>Oxford, UK</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">4329337</article-id><article-id pub-id-type="doi">10.1111/all.12480</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Articles</subject></subj-group></article-categories><title-group><article-title><SecTag type="TITLE"><text><SENT sid="0" pm="."><plain>Once-daily fluticasone furoate 50 mcg in mild-to-moderate asthma: a 24-week placebo-controlled randomized trial </plain></SENT>
</text></SecTag></article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Busse</surname><given-names>W W</given-names></name><xref ref-type="aff" rid="au1">1</xref><xref ref-type="corresp" rid="cor1"/></contrib><contrib contrib-type="author"><name><surname>Bateman</surname><given-names>E D</given-names></name><xref ref-type="aff" rid="au2">2</xref></contrib><contrib contrib-type="author"><name><surname>O'Byrne</surname><given-names>P M</given-names></name><xref ref-type="aff" rid="au3">3</xref></contrib><contrib contrib-type="author"><name><surname>Lötvall</surname><given-names>J</given-names></name><xref ref-type="aff" rid="au4">4</xref></contrib><contrib contrib-type="author"><name><surname>Woodcock</surname><given-names>A</given-names></name><xref ref-type="aff" rid="au5">5</xref></contrib><contrib contrib-type="author"><name><surname>Medley</surname><given-names>H</given-names></name><xref ref-type="aff" rid="au6">6</xref></contrib><contrib contrib-type="author"><name><surname>Forth</surname><given-names>R</given-names></name><xref ref-type="aff" rid="au7">7</xref></contrib><contrib contrib-type="author"><name><surname>Jacques</surname><given-names>L</given-names></name><xref ref-type="aff" rid="au6">6</xref></contrib><aff id="au1"><label>1</label><institution>Department of Medicine, University of Wisconsin</institution><addr-line>Madison, WI, USA</addr-line></aff><aff id="au2"><label>2</label><institution>Department of Medicine, University of Cape Town</institution><addr-line>Cape Town, South Africa</addr-line></aff><aff id="au3"><label>3</label><institution>Michael G DeGroote School of Medicine</institution><addr-line>Hamilton, ON, Canada</addr-line></aff><aff id="au4"><label>4</label><institution>Krefting Research Centre, University of Gothenburg</institution><addr-line>Gothenburg, Sweden</addr-line></aff><aff id="au5"><label>5</label><institution>Institute of Inflammation and Repair, University of Manchester</institution><addr-line>Manchester, UK</addr-line></aff><aff id="au6"><label>6</label><institution>Respiratory Medicines Development Centre, GlaxoSmithKline</institution><addr-line>London, UK</addr-line></aff><aff id="au7"><label>7</label><institution>Quantitative Sciences Division, GlaxoSmithKline</institution><addr-line>Research Triangle Park, NC, USA</addr-line></aff></contrib-group><author-notes><corresp id="cor1"><bold>Correspondence</bold> Professor William W. Busse, Department of Medicine, University of Wisconsin, K4/910, CSC, 600 Highland Avenue, Madison, WI 53792, USA., Tel.: +1 608 263 6183, Fax: +1 608 261 1191, E-mail: <email>wwb@medicine.wisc.edu</email></corresp><fn><p><text><SENT sid="1" pm="."><plain>Edited by: Douglas Robinson </plain></SENT>
</text></p></fn><fn><p><text><SENT sid="2" pm="."><plain>To cite this article: Busse WW, Bateman ED, O'Byrne PM, Lötvall J, Woodcock A, Medley H, Forth R, Jacques L. </plain></SENT>
<SENT sid="3" pm="."><plain>Once-daily fluticasone furoate 50 mcg in mild-to-moderate asthma: a 24-week placebo-controlled randomized trial. Allergy 2014; 69: 1522–1530. </plain></SENT>
</text></p></fn></author-notes><pub-date pub-type="ppub"><month>11</month><year>2014</year></pub-date><pub-date pub-type="epub"><day>22</day><month>8</month><year>2014</year></pub-date><volume>69</volume><issue>11</issue><fpage>1522</fpage><lpage>1530</lpage><history><date date-type="accepted"><day>04</day><month>7</month><year>2014</year></date></history><permissions><copyright-statement>© 2014 The Authors. <italic>Allergy</italic> Published by John Wiley &amp; Sons Ltd.</copyright-statement><copyright-year>2014</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/"><license-p>This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.</license-p></license></permissions><abstract><sec><title><text><SENT sid="4" pm="."><plain>Background </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="5" pm="."><plain>Inhaled glucocorticosteroids (ICS) are the mainstay of treatment in asthma. </plain></SENT>
<SENT sid="6" pm="."><plain>Fluticasone furoate (FF) is a novel, once-daily ICS asthma therapy. </plain></SENT>
<SENT sid="7" pm="."><plain>This study investigated the efficacy and safety of FF 50 mcg in patients with mild-to-moderate persistent asthma. </plain></SENT>
</text></SecTag></p></sec><sec sec-type="methods"><title><text><SENT sid="8" pm="."><plain>Methods </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="9" pm="."><plain>A 24-week, multicenter, randomized, placebo-controlled and active-controlled, double-blind, double-dummy, parallel-group phase III study. </plain></SENT>
<SENT sid="10" pm="."><plain>Three hundred and fifty-one patients (aged ≥12 years; uncontrolled by non-ICS therapy) were randomized to treatment (1 : 1 : 1) with once-daily FF 50 mcg dosed in the evening, twice-daily fluticasone propionate (FP) 100 mcg or placebo. </plain></SENT>
<SENT sid="11" pm="."><plain>The primary endpoint was change from baseline in evening trough forced expiratory volume in 1 s (FEV1) at Week 24. </plain></SENT>
<SENT sid="12" pm="."><plain>Secondary endpoints were change from baseline in the percentage of rescue-free 24-h periods (powered endpoint), change from baseline in evening and morning peak expiratory flow, change from baseline in the percentage of symptom-free 24-h periods and number of withdrawals due to lack of efficacy. </plain></SENT>
</text></SecTag></p></sec><sec><title><text><SENT sid="13" pm="."><plain>Results </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="14" pm="."><plain>Evening trough FEV1 at Week 24 was not statistically significantly increased with FF 50 mcg once-daily (37 ml [95% CI: −55, 128]; P = 0.430), but was with FP 100 mcg twice daily (102 ml [10, 194]; P = 0.030), vs placebo. </plain></SENT>
<SENT sid="15" pm="."><plain>No consistent trends were observed across other endpoints, including the powered secondary endpoint. </plain></SENT>
<SENT sid="16" pm="."><plain>No safety concerns were raised for either active treatment. </plain></SENT>
</text></SecTag></p></sec><sec><title><text><SENT sid="17" pm="."><plain>Conclusions </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="18" pm="."><plain>FP 100 mcg twice daily improved evening trough FEV1 in patients with mild-to-moderate persistent asthma, but FF 50 mcg once daily did not demonstrate a significant effect. </plain></SENT>
<SENT sid="19" pm="."><plain>Secondary endpoints showed variable results. </plain></SENT>
<SENT sid="20" pm="."><plain>No safety concerns were identified for FF or FP. </plain></SENT>
</text></SecTag></p></sec></abstract><SecTag type="KEYWORD"><kwd-group><kwd>fluticasone furoate</kwd><kwd>fluticasone propionate</kwd><kwd>inhaled corticosteroid</kwd><kwd>lung function</kwd><kwd>safety</kwd></kwd-group></SecTag></article-meta></front><body><p><text><SENT sid="21" pm="."><plain>Inhaled glucocorticosteroids (ICS) improve lung function and asthma control and are the mainstay of treatment for all severities of asthma (1, 2). </plain></SENT>
<SENT sid="22" pm="."><plain>Levels of poorly controlled asthma remain high despite the availability of effective anti-inflammatory treatments (3). </plain></SENT>
<SENT sid="23" pm="."><plain>Multiple factors are perceived to contribute to poor control, including suboptimal adherence to maintenance therapy (4). </plain></SENT>
<SENT sid="24" pm="."><plain>One approach to improving adherence is to reduce the frequency of dosing from twice daily to once daily (5–7). </plain></SENT>
</text></p><p><text><SENT sid="25" pm="."><plain>Fluticasone furoate (FF) is a new once-daily ICS for the treatment of asthma. </plain></SENT>
<SENT sid="26" pm="."><plain>FF is structurally distinct from fluticasone propionate (FP) (8) and has a longer duration of action in vitro (9). </plain></SENT>
<SENT sid="27" pm="."><plain>Once-daily FF at doses of 50–200 mcg has demonstrated efficacy with a good safety and tolerability profile in patients with asthma (10–12). </plain></SENT>
</text></p><p><text><SENT sid="28" pm="."><plain>A post hoc analysis of previous dose-ranging studies suggested that FF dosed at 50 mcg is more effective for patients with less severe asthma (&gt;65% predicted forced expiratory volume in 1s [FEV1]) than those with more severe disease (≤65% predicted FEV1) (13). </plain></SENT>
<SENT sid="29" pm="."><plain>Therefore, the objective of this placebo-controlled study was to evaluate the efficacy and safety of once-daily FF 50 mcg in patients with persistent asthma uncontrolled (&gt;60% predicted FEV1) by non-ICS therapy. </plain></SENT>
<SENT sid="30" pm="."><plain>Twice-daily FP 100 mcg was an active control, which is indicated as a low-dose treatment for asthma and was considered to be an appropriate step-up therapy for patients uncontrolled with SABA alone. </plain></SENT>
<SENT sid="31" pm="."><plain>The results of this post hoc analysis have been published in abstract form (14). </plain></SENT>
</text></p><SecTag type="METHODS"><sec sec-type="methods"><title><text><SENT sid="32" pm="."><plain>Methods </plain></SENT>
</text></title><sec><title><text><SENT sid="33" pm="."><plain>Patients </plain></SENT>
</text></title><p><text><SENT sid="34" pm="."><plain>Patients aged ≥12 years, diagnosed with asthma as defined by the NIH (15) for ≥12 weeks, using noncorticosteroid controllers and/or short-acting beta2-agonists (SABAs), demonstrating best FEV1 ≥60% predicted and reversibility of ≥12% and ≥200 ml following 2–4 inhalations of salbutamol at screening were eligible. </plain></SENT>
<SENT sid="35" pm="."><plain>ICS or long-acting beta2-agonist (LABA) use within 4 weeks of screening was not permitted. </plain></SENT>
<SENT sid="36" pm="."><plain>Further exclusion criteria are presented in Appendix S1. </plain></SENT>
</text></p><p><text><SENT sid="37" pm="."><plain>Patients stopped using noncorticosteroid controllers, and existing SABA medication was replaced with salbutamol at screening; salbutamol was not permitted within 6 h of clinic visits. </plain></SENT>
<SENT sid="38" pm="."><plain>After a 2-week run-in, patients with evening FEV1 ≥60% predicted and documented salbutamol use and/or asthma symptoms on ≥4 of the previous 7 days who had completed all morning and evening diary measures on ≥4 of the previous 7 days were randomized. </plain></SENT>
<SENT sid="39" pm="."><plain>Exclusion criteria at randomization are summarized in Appendix S1. </plain></SENT>
</text></p><p><text><SENT sid="40" pm="."><plain>All patients gave written informed consent prior to study entry. </plain></SENT>
<SENT sid="41" pm="."><plain>The study was approved by local ethics review committees and was conducted in accordance with the Declaration of Helsinki (16), Good Clinical Practice guidelines (17) and all applicable regulatory requirements. </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="42" pm="."><plain>Study design and treatments </plain></SENT>
</text></title><p><text><SENT sid="43" pm="."><plain>This phase III, multicenter, randomized, placebo-controlled and active-controlled, double-blind, double-dummy, and parallel-group study (GSK study number FFA115285; <ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov">http://www.clinicaltrials.gov</ext-link> registration number NCT01436110) was conducted at 34 centers in six countries (United States, Poland, Russia, Peru, Mexico, and the Netherlands) between September 21, 2011 and September 26, 2012. </plain></SENT>
<SENT sid="44" pm="."><plain>Patients were randomized (1 : 1 : 1) to receive (i) FF 50 mcg once daily in the evening via the ELLIPTA® dry powder inhaler (DPI) (emitted dose 46 mcg) and placebo DISKUS®1 morning and evening; (ii) FP 100 mcg twice daily via DISKUS inhaler and placebo ELLIPTA in the evening; or (iii) placebo ELLIPTA in the evening and placebo DISKUS twice daily. </plain></SENT>
<SENT sid="45" pm="."><plain>Patients were assigned to study treatment following a telephone call to the Registration and Medication Ordering System (RAMOS [GlaxoSmithKline, UK]) and randomized in accordance with a central randomization schedule generated by the sponsor using a validated computerized system (RandAll [GlaxoSmithKline, UK]). </plain></SENT>
<SENT sid="46" pm="."><plain>Study visits occurred at weeks 2, 4, 8, 12, 18, and 24, with a follow-up visit at Week 25; telephone contact at weeks 16 and 22 helped to monitor compliance. </plain></SENT>
<SENT sid="47" pm="."><plain>Patients recorded peak expiratory flow (PEF) measurements and symptoms twice daily on an electronic diary card. </plain></SENT>
<SENT sid="48" pm="."><plain>Restricted concomitant medications are shown in Appendix S2. </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="49" pm="."><plain>Outcome measurements </plain></SENT>
</text></title><p><text><SENT sid="50" pm="."><plain>The primary endpoint was change from baseline in evening predose, prebronchodilator (trough) FEV1 at Week 24. </plain></SENT>
<SENT sid="51" pm="."><plain>The powered secondary endpoint was change from baseline in the percentage of rescue-free 24-h periods during the 24-week treatment period. </plain></SENT>
<SENT sid="52" pm="."><plain>Other secondary endpoints were as follows: change from baseline in evening and morning PEF averaged over 24 weeks, change from baseline in the percentage of symptom-free 24-h periods over 24 weeks, and number of withdrawals due to lack of efficacy during the treatment period. </plain></SENT>
<SENT sid="53" pm="."><plain>Other endpoints included change from baseline in Asthma Control Test™ (ACT) score, percentage of patients with ACT score ≥20, change from baseline in Total Asthma Quality of Life Questionnaire (AQLQ[+12]) score (all at Week 24) and unscheduled asthma-related healthcare resource utilization. </plain></SENT>
</text></p><p><text><SENT sid="54" pm="."><plain>Safety endpoints were incidence of adverse events (AEs) and of protocol-defined severe asthma exacerbations during the treatment period. </plain></SENT>
<SENT sid="55" pm="."><plain>AEs were coded using the Medical Dictionary for Regulatory Activities. </plain></SENT>
<SENT sid="56" pm="."><plain>Suspected pneumonia was confirmed by X-ray. </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="57" pm="."><plain>Statistical analysis </plain></SENT>
</text></title><p><text><SENT sid="58" pm="."><plain>Recruitment of 330 patients was expected to give 104 evaluable patients per treatment group. </plain></SENT>
<SENT sid="59" pm="."><plain>This would provide 94% power to detect a 200 ml treatment difference in trough FEV1, and 95% power to detect a treatment difference of 15% change from baseline in percentage of rescue-free 24-h periods for FF vs placebo. </plain></SENT>
<SENT sid="60" pm="."><plain>The overall power to detect treatment differences for FF vs placebo across the primary and powered secondary endpoints was 90%. </plain></SENT>
</text></p><p><text><SENT sid="61" pm="."><plain>The primary and secondary endpoints of rescue-free and symptom-free 24-h periods and evening and morning PEF were analyzed using an analysis of covariance (ancova) model adjusted for baseline, region, gender, age, and treatment group. </plain></SENT>
<SENT sid="62" pm="."><plain>An additional sensitivity analysis was performed for the primary endpoint using a repeated measures model adjusted for baseline FEV1, region, gender, age, visit, and treatment group. </plain></SENT>
<SENT sid="63" pm="."><plain>This model also contained interaction terms for visit-by-treatment and visit-by-baseline interaction term. </plain></SENT>
<SENT sid="64" pm="."><plain>Withdrawals due to lack of efficacy were analyzed using Fisher's Exact test. </plain></SENT>
<SENT sid="65" pm="."><plain>Details of analyses used for the other endpoints are summarized in Appendix S3. </plain></SENT>
<SENT sid="66" pm="."><plain>The intent-to-treat (ITT) population was the primary population for all efficacy and safety analyses, and comprised all patients that were randomized and received at least one dose of study medication. </plain></SENT>
</text></p><p><text><SENT sid="67" pm="."><plain>Data were analyzed using a closed, step-down statistical hierarchy, whereby failure to achieve significance (P &lt; 0.05) for the primary treatment comparison of FF vs placebo, at any point in the hierarchy, meant that statistical significance could not be inferred for the remaining endpoints, and these would be interpreted as descriptive only. </plain></SENT>
<SENT sid="68" pm="."><plain>The hierarchy order was as follows: (i) trough FEV1, (ii) rescue-free 24-h periods, (iii) evening PEF, (iv) morning PEF, (v) symptom-free 24-h periods, (vi) withdrawals due to lack of efficacy. </plain></SENT>
</text></p></sec></sec></SecTag><SecTag type="RESULTS"><sec sec-type="results"><title><text><SENT sid="69" pm="."><plain>Results </plain></SENT>
</text></title><sec><title><text><SENT sid="70" pm="."><plain>Study population </plain></SENT>
</text></title><p><text><SENT sid="71" pm="."><plain>Six hundred and fifty-five patients were screened, 351 were randomized, 347 were included in the ITT population, and 263 (76%) completed the study (Fig. 1). </plain></SENT>
<SENT sid="72" pm="."><plain>Patient demographics and screening/baseline characteristics were similar across treatment groups (Table 1). </plain></SENT>
<SENT sid="73" pm="."><plain>Adolescents (aged 12–17 years) comprised 15% of the ITT population. </plain></SENT>
<SENT sid="74" pm="."><plain>Mean % predicted FEV1 at baseline was high across all treatment groups (80.65–81.63%). </plain></SENT>
<SENT sid="75" pm="."><plain>Use of concomitant medications is summarized in Appendix S4. </plain></SENT>
<SENT sid="76" pm="."><plain>Treatment compliance was high across all treatment groups with ELLIPTA (97.5–98.6%) and DISKUS (93.7–95.0%). </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="tbl1" position="float"><label>Table 1</label><caption><p><text><SENT sid="77" pm="."><plain>Patient demographics and lung function at screening/baseline (intent-to-treat population) </plain></SENT>
</text></p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"/><th align="left" valign="bottom" rowspan="1" colspan="1"><text><SENT sid="78" pm="."><plain>Placebo (n = 115) </plain></SENT>
</text></th><th align="left" valign="bottom" rowspan="1" colspan="1"><text><SENT sid="79" pm="."><plain>FF 50 mcg OD PM (n = 117) </plain></SENT>
</text></th><th align="left" valign="bottom" rowspan="1" colspan="1"><text><SENT sid="80" pm="."><plain>FP 100 mcg BD (n = 115) </plain></SENT>
</text></th><th align="left" valign="bottom" rowspan="1" colspan="1"><text><SENT sid="81" pm="."><plain>Total (N = 347) </plain></SENT>
</text></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="82" pm="."><plain>Age, mean (SD), years </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="83" pm="."><plain>37.6 (18.03) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="84" pm="."><plain>35.4 (14.64) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="85" pm="."><plain>36.2 (16.95) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="86" pm="."><plain>36.4 (16.57) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="87" pm="."><plain>Age range, years </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="88" pm="."><plain>12–77 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="89" pm="."><plain>12–77 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="90" pm="."><plain>12–81 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="91" pm="."><plain>12–81 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="92" pm="."><plain>Gender: female, n (%) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="93" pm="."><plain>81 (70) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="94" pm="."><plain>72 (62) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="95" pm="."><plain>76 (66) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="96" pm="."><plain>229 (66) </plain></SENT>
</text></td></tr><tr><td align="left" colspan="5" rowspan="1"><text><SENT sid="97" pm="."><plain>Race, n (%) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="98" pm="."><plain> White </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="99" pm="."><plain>52 (45) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="100" pm="."><plain>55 (47) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="101" pm="."><plain>54 (47) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="102" pm="."><plain>161 (46) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="103" pm="."><plain> American Indian or Alaska Native </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="104" pm="."><plain>31 (27) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="105" pm="."><plain>30 (26) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="106" pm="."><plain>34 (30) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="107" pm="."><plain>95 (27) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="108" pm="."><plain> American Indian or Alaska Native and White </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="109" pm="."><plain>21 (18) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="110" pm="."><plain>16 (14) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="111" pm="."><plain>18 (16) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="112" pm="."><plain>55 (16) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="113" pm="."><plain> African American/African Heritage </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="114" pm="."><plain>9 (8) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="115" pm="."><plain>14 (12) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="116" pm="."><plain>9 (8) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="117" pm="."><plain>32 (9) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="118" pm="."><plain> Other* </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="119" pm="."><plain>2 (2) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="120" pm="."><plain>2 (2) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="121" pm="."><plain>0 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="122" pm="."><plain>4 (1) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="123" pm="."><plain>Percent reversibility FEV1†, % </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="124" pm="."><plain>22.98 (11.090) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="125" pm="."><plain>21.49 (8.247) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="126" pm="."><plain>23.46 (10.459) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="127" pm="."><plain>22.64 (10.003) </plain></SENT>
</text></td></tr><tr><td align="left" colspan="5" rowspan="1"><text><SENT sid="128" pm="."><plain>Baseline characteristics, mean (SD) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="129" pm="."><plain> Prebronchodilator FEV1 (l) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="130" pm="."><plain>2.475 (0.7395) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="131" pm="."><plain>2.653 (0.6834) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="132" pm="."><plain>2.582 (0.8065) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="133" pm="."><plain>2.571 (0.7460) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="134" pm="."><plain> Percent predicted FEV1, % </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="135" pm="."><plain>80.65 (13.396) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="136" pm="."><plain>81.63 (12.566) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="137" pm="."><plain>80.77 (14.485) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="138" pm="."><plain>81.02 (13.468) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="139" pm="."><plain> Rescue-free 24-h periods, % </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="140" pm="."><plain>11.1 (24.01) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="141" pm="."><plain>11.8 (26.25) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="142" pm="."><plain>6.7 (17.20) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="143" pm="."><plain>NA </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="144" pm="."><plain> Symptom-free 24-h periods, % </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="145" pm="."><plain>4.3 (13.48) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="146" pm="."><plain>7.1 (20.61) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="147" pm="."><plain>5.4 (18.27) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="148" pm="."><plain>NA </plain></SENT>
</text></td></tr></tbody></table><table-wrap-foot><fn><p><text><SENT sid="149" pm="."><plain>BD, twice daily; FEV1, forced expiratory volume in 1 s; FF, fluticasone furoate; FP, fluticasone propionate; NA, not applicable; OD, once daily; PM, evening; SD, standard deviation. </plain></SENT>
</text></p></fn><fn id="tf1-1"><label>*</label><p><text><SENT sid="150" pm="."><plain>Other = Asian, African American/African Heritage and American Indian or Alaska Native, and Asian and White. </plain></SENT>
</text></p></fn><fn id="tf1-2"><label>†</label><p><text><SENT sid="151" pm="."><plain>Recorded at screening. n = 144, 116, 114, and 344, respectively, for the Placebo, FF 50 mcg OD, FP 100 mcg BD, and Total groups. </plain></SENT>
</text></p></fn></table-wrap-foot></table-wrap></SecTag><SecTag type="FIG"><fig id="fig01" position="float"><label>Figure 1</label><caption><p><text><SENT sid="152" pm="."><plain>Patient disposition. </plain></SENT>
<SENT sid="153" pm="."><plain>FF, fluticasone furoate; FP, fluticasone propionate; ITT, intent-to-treat. </plain></SENT>
</text></p></caption><graphic xlink:href="all0069-1522-f1"/></fig></SecTag></sec><sec><title><text><SENT sid="154" pm="."><plain>Efficacy </plain></SENT>
</text></title><sec><title><text><SENT sid="155" pm="."><plain>Primary endpoint </plain></SENT>
</text></title><p><text><SENT sid="156" pm="."><plain>Improvement in change from baseline in predose evening trough FEV1 at Week 24 was not significant vs placebo for FF (37 ml, P = 0.430), but was for FP (102 ml, P = 0.030) (Table 2). </plain></SENT>
<SENT sid="157" pm="."><plain>The repeated measures analysis showed sustained improvement in trough FEV1 over the treatment period in all treatment groups, which was not statistically significant for either treatment vs placebo at Week 24 (Fig. 2). </plain></SENT>
<SENT sid="158" pm="."><plain>Because of the statistical hierarchy, the lack of statistical significance on the primary endpoint meant that all subsequent endpoints were interpreted as descriptive only for the FF vs placebo treatment comparison. </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="tbl2" position="float"><label>Table 2</label><caption><p><text><SENT sid="159" pm="."><plain>Statistical analysis of primary (change from baseline in trough FEV1) and powered secondary endpoints at Week 24 (intent-to-treat population) </plain></SENT>
</text></p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"/><th align="left" valign="bottom" rowspan="1" colspan="1"><text><SENT sid="160" pm="."><plain>Placebo (n = 115) </plain></SENT>
</text></th><th align="left" valign="bottom" rowspan="1" colspan="1"><text><SENT sid="161" pm="."><plain>FF 50 mcg OD PM (n = 117) </plain></SENT>
</text></th><th align="left" valign="bottom" rowspan="1" colspan="1"><text><SENT sid="162" pm="."><plain>FP 100 mcg BD (n = 115) </plain></SENT>
</text></th></tr></thead><tbody><tr><td align="left" colspan="4" rowspan="1"><text><SENT sid="163" pm="."><plain>Trough FEV1 (Week 24), ml* </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="164" pm="."><plain> n </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="165" pm="."><plain>111 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="166" pm="."><plain>116 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="167" pm="."><plain>112 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="168" pm="."><plain> LS mean </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="169" pm="."><plain>2653 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="170" pm="."><plain>2690 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="171" pm="."><plain>2755 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="172" pm="."><plain> LS mean change from baseline (SE) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="173" pm="."><plain>89 (33.1) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="174" pm="."><plain>126 (32.3) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="175" pm="."><plain>191 (32.8) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="176" pm="."><plain> Treatment difference vs placebo (95% CI) </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="177" pm="."><plain>37 (−55, 128)P = 0.430 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="178" pm="."><plain>102 (10, 194)P = 0.030 </plain></SENT>
</text></td></tr><tr><td align="left" colspan="4" rowspan="1"><text><SENT sid="179" pm="."><plain>Percentage of rescue-free 24-h periods (Weeks 1–24) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="180" pm="."><plain> n </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="181" pm="."><plain>114 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="182" pm="."><plain>116 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="183" pm="."><plain>113 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="184" pm="."><plain> LS mean change from baseline, % (SE) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="185" pm="."><plain>21.1 (3.20) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="186" pm="."><plain>28.9 (3.17) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="187" pm="."><plain>31.7 (3.21) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="188" pm="."><plain> Treatment difference vs placebo (95% CI)† </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="189" pm="."><plain>7.8 (−1.0, 16.7) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="190" pm="."><plain>10.6 (1.7, 19.6) </plain></SENT>
</text></td></tr></tbody></table><table-wrap-foot><fn><p><text><SENT sid="191" pm="."><plain>BD, twice daily; CI, confidence interval; FEV1, forced expiratory volume in 1 s; FF, fluticasone furoate; FP, fluticasone propionate; LS, least squares; NA, not applicable; OD, once daily; PM, evening; SE, standard error. </plain></SENT>
</text></p></fn><fn><p><text><SENT sid="192" pm="."><plain>Analysis performed using ancova with covariates of baseline, region, gender, age, and treatment. </plain></SENT>
</text></p></fn><fn id="tf2-1"><label>*</label><p><text><SENT sid="193" pm="."><plain>Last observation carried forward (LOCF) was used to impute missing data. </plain></SENT>
</text></p></fn><fn id="tf2-2"><label>†</label><p><text><SENT sid="194" pm="."><plain>No inferences (P-values) provided as primary treatment comparison was not statistically significant. </plain></SENT>
</text></p></fn></table-wrap-foot></table-wrap></SecTag><SecTag type="FIG"><fig id="fig02" position="float"><label>Figure 2</label><caption><p><text><SENT sid="195" pm="."><plain>Repeated measures analysis of mean change from baseline (95% CI) in trough FEV1 (l) (intent-to-treat population). </plain></SENT>
<SENT sid="196" pm="."><plain>BD, twice daily; CI, confidence interval; FEV1, forced expiratory volume in 1 s; FF, fluticasone furoate; FP, fluticasone propionate; LS, least squares; OD, once daily. </plain></SENT>
</text></p></caption><graphic xlink:href="all0069-1522-f2"/></fig></SecTag></sec><sec><title><text><SENT sid="197" pm="."><plain>Powered secondary endpoint </plain></SENT>
</text></title><p><text><SENT sid="198" pm="."><plain>The percentage of rescue-free 24-h periods increased from baseline over Weeks 0–24 in all treatment groups (Table 2); mean improvements, vs placebo, were not statistically significant for FF (7.8%; 95% confidence interval [CI]: −1.0, 16.7), but were for FP (10.6%; 95% CI: 1.7, 19.6). </plain></SENT>
<SENT sid="199" pm="."><plain>The number of additional rescue-free days per week, vs placebo, was similar for FF (0.5) and FP (0.7). </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="200" pm="."><plain>Secondary and other endpoints </plain></SENT>
</text></title><p><text><SENT sid="201" pm="."><plain>Over the 24-week treatment period, mean change (95% CI) from baseline vs placebo in evening PEF was 17.2 l/min (5.9, 28.6) for FF and 4.3 l/min (−7.0, 15.7) for FP (Fig. 3); change in morning PEF was 19.2 l/min (8.5, 29.9) for FF and 10.6 l/min (−0.2, 21.3) for FP. </plain></SENT>
<SENT sid="202" pm="."><plain>Changes from baseline in percentage of symptom-free 24-h periods, vs placebo, were 8.3 (0.3, 16.3) for FF and 7.5 (−0.5, 15.5) for FP (Fig. 3). </plain></SENT>
<SENT sid="203" pm="."><plain>The equivalent number of additional symptom-free days per week, vs placebo, was similar for FF (0.6) and FP (0.5). </plain></SENT>
<SENT sid="204" pm="."><plain>There were more withdrawals due to lack of efficacy with placebo (20%) than with FF (12%) or FP (8%) (Appendix S5). </plain></SENT>
</text></p><SecTag type="FIG"><fig id="fig03" position="float"><label>Figure 3</label><caption><p><text><SENT sid="205" pm="."><plain>Summary of change from baseline for selected secondary and other efficacy endpoints (intent-to-treat population). </plain></SENT>
<SENT sid="206" pm="."><plain>Due to the failure to achieve statistical significance of the primary endpoint in the statistical hierarchy, data for these endpoints can be interpreted as descriptive only. </plain></SENT>
<SENT sid="207" pm="."><plain>Data are mean and 95% confidence interval. </plain></SENT>
<SENT sid="208" pm="."><plain>AM, morning; BD, twice daily; FF, fluticasone furoate; FP, fluticasone propionate; OD, once daily; PM, evening. </plain></SENT>
</text></p></caption><graphic xlink:href="all0069-1522-f3"/></fig></SecTag><p><text><SENT sid="209" pm="."><plain>Mean change (95% CI) from baseline in ACT score, vs placebo, was 0.9 (−0.1, 2.0) with FF and 1.0 (−0.1, 2.0) with FP (Fig. 3). </plain></SENT>
<SENT sid="210" pm="."><plain>Most (87–90%) patients reported an ACT score &lt;20 at baseline; a greater proportion of patients receiving FF (65%) and FP (63%) than placebo (56%) reported an ACT score ≥20 at Week 24. </plain></SENT>
<SENT sid="211" pm="."><plain>No improvement over placebo was seen in AQLQ (+12) score with either active treatment (Fig. 3). </plain></SENT>
<SENT sid="212" pm="."><plain>Seven patients reported unscheduled healthcare resource utilization (4 placebo, 2 FF, 1 FP), five due to a severe asthma exacerbation (4 placebo, 1 FF). </plain></SENT>
</text></p></sec></sec><sec><title><text><SENT sid="213" pm="."><plain>Safety assessments </plain></SENT>
</text></title><p><text><SENT sid="214" pm="."><plain>The incidence of on-treatment AEs was 48–56% across treatment groups, with headache, nasopharyngitis, pharyngitis, and upper respiratory tract infections occurring most frequently overall (Table 3). </plain></SENT>
<SENT sid="215" pm="."><plain>Five patients withdrew due to AEs: n = 2 with placebo (respiratory tract infection; pneumonia); n = 1 with FF (apathy, fatigue, irritability, and weight increase); n = 2 with FP (n = 1: dermatitis; n = 1: dyspnea and sensory disturbance, both of which were ongoing at last contact). </plain></SENT>
<SENT sid="216" pm="."><plain>The incidence of treatment-related AEs was 3% in all treatment groups (n = 3 placebo, 4 FF, 4 FP). </plain></SENT>
<SENT sid="217" pm="."><plain>AEs of special interest were reported by 27 patients (12 placebo, 4 FF, 11 FP). </plain></SENT>
<SENT sid="218" pm="."><plain>Oral candidiasis (n = 2 with FF) and oral candidiasis and dysphonia (n = 1 with FP) were the only AEs that were both associated with ICS and considered treatment related. </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="tbl3" position="float"><label>Table 3</label><caption><p><text><SENT sid="219" pm="."><plain>Summary of most frequent on-treatment AEs and serious AEs (safety population) </plain></SENT>
</text></p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"/><th align="left" valign="bottom" rowspan="1" colspan="1"><text><SENT sid="220" pm="."><plain>Placebo (n = 115) </plain></SENT>
</text></th><th align="left" valign="bottom" rowspan="1" colspan="1"><text><SENT sid="221" pm="."><plain>FF 50 mcg OD PM (n = 117) </plain></SENT>
</text></th><th align="left" valign="bottom" rowspan="1" colspan="1"><text><SENT sid="222" pm="."><plain>FP 100 mcg BD (n = 115) </plain></SENT>
</text></th></tr></thead><tbody><tr><td align="left" colspan="4" rowspan="1"><text><SENT sid="223" pm="."><plain>AEs </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="224" pm="."><plain> On-treatment </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="225" pm="."><plain>64 (56) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="226" pm="."><plain>56 (48) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="227" pm="."><plain>59 (51) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="228" pm="."><plain> On-treatment, treatment related* </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="229" pm="."><plain>3 (3) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="230" pm="."><plain>4 (3) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="231" pm="."><plain>4 (3) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="232" pm="."><plain> On-treatment, leading to withdrawal </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="233" pm="."><plain>2 (2) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="234" pm="."><plain>1 (&lt;1) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="235" pm="."><plain>2 (2) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="236" pm="."><plain> Post-treatment </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="237" pm="."><plain>0 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="238" pm="."><plain>0 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="239" pm="."><plain>1 (&lt;1) </plain></SENT>
</text></td></tr><tr><td align="left" colspan="4" rowspan="1"><text><SENT sid="240" pm="."><plain>Serious AEs </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="241" pm="."><plain> On-treatment </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="242" pm="."><plain>3 (3) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="243" pm="."><plain>0 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="244" pm="."><plain>1 (&lt;1) </plain></SENT>
</text></td></tr><tr><td align="left" colspan="4" rowspan="1"><text><SENT sid="245" pm="."><plain>On-treatment AEs occurring in ≥5% patients in any treatment group </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="246" pm="."><plain> Headache </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="247" pm="."><plain>13 (11) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="248" pm="."><plain>17 (15) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="249" pm="."><plain>12 (10) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="250" pm="."><plain> Nasopharyngitis </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="251" pm="."><plain>6 (5) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="252" pm="."><plain>8 (7) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="253" pm="."><plain>12 (10) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="254" pm="."><plain> Pharyngitis </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="255" pm="."><plain>10 (9) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="256" pm="."><plain>7 (6) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="257" pm="."><plain>5 (4) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="258" pm="."><plain> Upper respiratory tract infection </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="259" pm="."><plain>3 (3) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="260" pm="."><plain>6 (5) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="261" pm="."><plain>6 (5) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="262" pm="."><plain> Influenza </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="263" pm="."><plain>4 (3) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="264" pm="."><plain>4 (3) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="265" pm="."><plain>6 (5) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="266" pm="."><plain> Oropharyngeal pain </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="267" pm="."><plain>6 (5) </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="268" pm="."><plain>0 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="269" pm="."><plain>2 (2) </plain></SENT>
</text></td></tr></tbody></table><table-wrap-foot><fn><p><text><SENT sid="270" pm="."><plain>AE, adverse event; BD, twice daily; FF, fluticasone furoate; FP, fluticasone propionate; OD, once daily; PM, evening. </plain></SENT>
</text></p></fn><fn><p><text><SENT sid="271" pm="."><plain>All data are n (%). </plain></SENT>
</text></p></fn><fn id="tf3-1"><label>*</label><p><text><SENT sid="272" pm="."><plain>Adverse events deemed treatment related by the investigator prior to unblinding. </plain></SENT>
</text></p></fn></table-wrap-foot></table-wrap></SecTag><p><text><SENT sid="273" pm="."><plain>Four patients experienced on-treatment serious AEs, three with placebo (pneumonia, cholelithiasis, and premenstrual syndrome) and one with FP (dermatitis); none were considered treatment related, and only the incidence of pneumonia with placebo and the incidence of dermatitis with FP led to withdrawal. </plain></SENT>
<SENT sid="274" pm="."><plain>There were no post-treatment serious AEs and no deaths. </plain></SENT>
<SENT sid="275" pm="."><plain>Severe asthma exacerbations were experienced by more patients with placebo (n = 7) than with FF (n = 3) or FP (n = 1); all exacerbations were treated with systemic/oral corticosteroids. </plain></SENT>
<SENT sid="276" pm="."><plain>Pneumonia was confirmed by chest X-ray in two patients (1 placebo, 1 FP); neither was considered to be treatment related. </plain></SENT>
</text></p></sec></sec></SecTag><SecTag type="DISCUSS"><sec sec-type="discussion"><title><text><SENT sid="277" pm="."><plain>Discussion </plain></SENT>
</text></title><p><text><SENT sid="278" pm="."><plain>Significant treatment benefits were not observed for the primary endpoint of change from baseline in evening trough FEV1 or for the secondary endpoint of change from baseline in percentage of rescue-free 24-h periods for the comparison of once-daily FF 50 mcg vs placebo in patients with mild-to-moderate asthma; however, there were numerical improvements with FF 50 mcg. </plain></SENT>
<SENT sid="279" pm="."><plain>Significant treatment benefits were observed for the comparison of twice-daily FP 100 mcg vs placebo. </plain></SENT>
<SENT sid="280" pm="."><plain>This study was not powered to formally compare FF with FP; furthermore, no consistent trend was observed in any treatment group across the remaining endpoints. </plain></SENT>
<SENT sid="281" pm="."><plain>No safety concerns were identified for once-daily FF 50 mcg or twice-daily FP 100 mcg. </plain></SENT>
</text></p><p><text><SENT sid="282" pm="."><plain>GINA guidelines recommend using the lowest dose of ICS possible to maintain control of asthma (2). </plain></SENT>
<SENT sid="283" pm="."><plain>Thus, the purpose of our study was to investigate FF 50 mcg as a potentially appropriate dose in patients with mild-to-moderate asthma (FEV1 ≥60% predicted, not using ICS). </plain></SENT>
<SENT sid="284" pm="."><plain>The finding that FF 50 mcg was not significantly better than placebo in improving evening trough FEV1 is not consistent with previous observations. </plain></SENT>
<SENT sid="285" pm="."><plain>Other studies in similar patient populations have reported statistically significant effects of once-daily FF 50 mcg, vs placebo, on evening trough FEV1 when dosed for 8 weeks (129 ml, P = 0.033) (10) or 12 weeks (120 ml, P = 0.012) (18). </plain></SENT>
<SENT sid="286" pm="."><plain>There are a number of possible explanations for the discrepant findings. </plain></SENT>
<SENT sid="287" pm="."><plain>In our study, patients had a baseline mean % predicted FEV1 of 81.02%; therefore, a ceiling effect may have limited the potential for a response to treatment relative to more patients with severe asthma (% predicted FEV1 &lt;70%) (19), as were included in the 8-week study (10). </plain></SENT>
<SENT sid="288" pm="."><plain>Assessment of morning trough FEV1 may have maximized the opportunity to detect a difference, as lung function is naturally at a minimum at this time (20); however, a similar patient population was treated with FF 50 mcg in the 12-week study (18), contradicting this possible explanation. </plain></SENT>
<SENT sid="289" pm="."><plain>Additionally, in this study, the mean prebronchodilator FEV1 improved by 143 ml during run-in, indicating that 2 weeks may not have been long enough to minimize the placebo response during the study. </plain></SENT>
<SENT sid="290" pm="."><plain>These explanations are unlikely to explain fully the lack of significance for the primary endpoint with FF, as statistical significance relative to placebo was achieved (P &lt; 0.05) with FP, showing that the study had assay sensitivity to detect a treatment difference. </plain></SENT>
<SENT sid="291" pm="."><plain>The FP findings conflict with those from the 8-week study (10) in which FP 100 mcg twice daily did not significantly improve trough FEV1 compared with placebo, suggesting that low-dose ICS will demonstrate efficacy in some studies, but not in others, and that some patients with mild-to-moderate asthma who are uncontrolled with SABA alone will require further step-up therapy. </plain></SENT>
<SENT sid="292" pm="."><plain>In other studies, higher doses of FF once-daily have proven to be as efficacious as FP twice-daily. </plain></SENT>
<SENT sid="293" pm="."><plain>FF 100 mcg once-daily demonstrated similar efficacy to FP 250 mcg twice daily across a range of endpoints (21), and FF 200 mcg once-daily has demonstrated similar efficacy to FP 500 mcg twice-daily in improving trough FEV1 over 24 weeks, in patients with moderate-to-severe persistent asthma (22). </plain></SENT>
</text></p><p><text><SENT sid="294" pm="."><plain>No statistical inference could be drawn for FF, vs placebo, for any of the remaining endpoints because of the statistical hierarchy. </plain></SENT>
<SENT sid="295" pm="."><plain>Increases from baseline in rescue-free and symptom-free 24-h periods were observed in all treatment groups with numerical improvements relative to placebo observed for FF and FP; improvements in rescue-free 24-h periods were statistically significant with FP, but not with FF. </plain></SENT>
<SENT sid="296" pm="."><plain>The improvements with FF 50 mcg were smaller than those observed in previous studies over 8 weeks (10) and 12 weeks (18). </plain></SENT>
</text></p><p><text><SENT sid="297" pm="."><plain>Poor correlation between treatment effects on FEV1 and PEF was seen in our study and although unusual, such poor correlation has been observed by others (23, 24). </plain></SENT>
<SENT sid="298" pm="."><plain>Despite changes in FEV1 with FF not being significantly better than placebo, numerical improvements in evening and morning PEF, vs placebo, were large. </plain></SENT>
<SENT sid="299" pm="."><plain>The opposite was observed with FP and improvements in PEF were modest and not statistically significant. </plain></SENT>
<SENT sid="300" pm="."><plain>Although significance cannot be inferred for the PEF endpoints, the observed numerical improvements with FF may be relevant because of patients' limited volume for improvement in FEV1. </plain></SENT>
<SENT sid="301" pm="."><plain>No clinically meaningful improvements in ACT (+≥3) (25) or Total AQLQ (+12) (+≥0.5) (26) score were observed with either active treatment compared with placebo, findings that accord with those from the 12-week study (18). </plain></SENT>
</text></p><p><text><SENT sid="302" pm="."><plain>No safety concerns were raised for FF or FP. </plain></SENT>
<SENT sid="303" pm="."><plain>The incidence of AEs was similar in all three treatment groups, consistent with previous findings for FF 50 mcg and FP 100 mcg (10, 18). </plain></SENT>
<SENT sid="304" pm="."><plain>Steroid-related AEs were not anticipated for the strengths of FF or FP used in this study (10, 27); however, there were reports of oral candidiasis with both treatments. </plain></SENT>
<SENT sid="305" pm="."><plain>There were no reports of pneumonia with FF, but there was a single pneumonia event in each of the FP and placebo groups. </plain></SENT>
<SENT sid="306" pm="."><plain>The low frequency of exacerbations was as expected for the cohort of patients studied. </plain></SENT>
</text></p><p><text><SENT sid="307" pm="."><plain>The strengths of this study included the 24-week treatment period, the longest to date for FF at this dose, high levels of compliance across all treatment groups, and the inclusion of FP as a positive control. </plain></SENT>
<SENT sid="308" pm="."><plain>Potential limitations include the substantial placebo response for the primary endpoint and the fact that the study was not formally powered to compare FF with FP. </plain></SENT>
</text></p><p><text><SENT sid="309" pm="."><plain>In conclusion, once-daily FF 50 mcg was not effective in improving trough FEV1 in this population of patients with mild-to-moderate persistent asthma, as it did not produce a significantly greater improvement than placebo after 24 weeks. </plain></SENT>
<SENT sid="310" pm="."><plain>These results are inconsistent with previous findings. </plain></SENT>
<SENT sid="311" pm="."><plain>A statistically significant improvement was seen for the same endpoint with twice-daily FP 100 mcg. </plain></SENT>
<SENT sid="312" pm="."><plain>Both FF and FP were well tolerated, and no safety issues of clinical concern were identified. </plain></SENT>
</text></p></sec></SecTag></body><back><SecTag type="ACK_FUND"><ack><p><text4fund><text><SENT sid="313" pm="."><plain>Editorial support in the form of development of the draft outline in consultation with the authors was provided by Ian Grieve, PhD, at Gardiner-Caldwell Communications (Macclesfield, UK), while development of the manuscript first draft in consultation with the authors, editorial suggestions to draft versions of this paper, assembling tables and figures, collating author comments, copyediting, fact checking, referencing and graphic services was provided by Laura Maguire, MChem, at Gardiner-Caldwell Communications (Macclesfield, UK). </plain></SENT>
<SENT sid="314" pm="."><plain>Editorial support was funded by GlaxoSmithKline. </plain></SENT>
</text></text4fund></p></ack></SecTag><SecTag type="ACK_FUND"><sec><title>Funding</title><p><text4fund><text><SENT sid="315" pm="."><plain>This study was funded by GlaxoSmithKline (GSK study number FFA115285; <ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov">http://www.clinicaltrials.gov</ext-link> registration number NCT01436110). </plain></SENT>
</text></text4fund></p></sec></SecTag><SecTag type="AUTH_CONT"><sec><title>Author contributions</title><p>W.W.B, E.D.B, P.M.O'B, J.L, A.W, R.F and L.J were involved in the conception and design of the study; R.F was involved in data analysis; W.W.B, E.D.B, P.M.O'B, J.L, A.W, H.M. R.F, and L.J were involved in the interpretation of data. The study was sponsored by GlaxoSmithKline. Employees of the sponsor were involved in the conception, design and conduct of the study, and in data collection and analysis. All authors, including authors employed by the sponsor, participated in the development of the manuscript and had access to the data from the study. The decision to submit for publication was that of the authors alone.</p></sec></SecTag><SecTag type="COMP_INT"><sec><title>Conflicts of interest</title><p>W.W.B. has served as a consultant to Amgen, AstraZeneca, Boehringer Ingelheim, Genentech, GlaxoSmithKline, MedImmune, and Novartis; served on advisory boards for Merck Sharpe, and Dohme; and received research funding from AstraZeneca. E.D.B. has served as a consultant to AlkAbello, Almirall, Boehringer Ingelheim, Cephalon, Hoffman la Roche, ICON, and MS Consulting Group; been on advisory boards for Almirall, AstraZeneca, Boehringer Ingelheim, Elevation Pharma, Forest, GlaxoSmithKline, Merck, Napp, Novartis, and Takeda; and received lecture fees from AlkAbello, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Novartis, Pfizer, Takeda, and TEVA; and his institution has received remuneration for participation in clinical trials sponsored by Actelion, Aeras, Almirall, AstraZeneca, Boehringer Ingelheim, Cephalon, Forest, GlaxoSmithKline, Hoffman La Roche, Merck, Novartis, Takeda, and TEVA. P.M.O'B. has served as a consultant to AstraZeneca, Almirall, Boehringer Ingelheim, GlaxoSmithKline, and Merck; has served on advisory boards for AIM, Altair, Boehringer, GlaxoSmithKline, Medimmune, and Merck; has received lecture fees from Chiesi; and has received research funding from Amgen, AstraZeneca, Asmacure, Genentech, and Ono. J.L. has served as a consultant to and received lecture fees from AstraZeneca, GlaxoSmithKline, Merck Sharpe and Dohme, Novartis, and UCB Pharma; has been partly covered by some of these companies to attend previous scientific meetings including the ERS and the AAAAI; has provided expert testimony for Barr Pharmaceuticals; and has participated in clinical research studies sponsored by AstraZeneca, GlaxoSmithKline, Merck Sharpe and Dohme, and Novartis. A.W. has served as consultant to Almirall, Chiesi, Cytos, and GlaxoSmithKline; and has received lecture fees and research grants from GlaxoSmithKline. R.F., H.V.M., and L.J. are employees of and hold stock in GlaxoSmithKline.</p></sec></SecTag><notes><title>Notes</title><fn-group><fn id="fn1"><label>1</label><p><text><SENT sid="316" pm="."><plain>ELLIPTA® and DISKUS® are trademarks of the GSK group of companies. </plain></SENT>
</text></p></fn></fn-group></notes><SecTag type="REF"><ref-list><title>References</title><ref id="b1"><text><SENT sid="317" pm="."><plain>1FantaCHDrug therapy: asthmaN Engl J Med20093601002101419264689 </plain></SENT>
</text></ref><ref id="b2"><text><SENT sid="318" pm="."><plain>2Global Initiative for Asthma (GINA)Global Strategy for Asthma Management and Prevention 2012. </plain></SENT>
<SENT sid="319" pm="."><plain>Available at: <ext-link ext-link-type="uri" xlink:href="http://www.ginasthma.org/local/uploads/files/GINA_Report_March13.pdf">http://www.ginasthma.org/local/uploads/files/GINA_Report_March13.pdf</ext-link>. </plain></SENT>
<SENT sid="320" pm="."><plain>Last accessed 11 April 2014 </plain></SENT>
</text></ref><ref id="b3"><text><SENT sid="321" pm="."><plain>3DemolyPAnnunziataKGubbaEAdamekLRepeated cross-sectional survey of patient-reported asthma control in Europe in the past 5 yearsEur Respir Rev201221667422379176 </plain></SENT>
</text></ref><ref id="b4"><text><SENT sid="322" pm="."><plain>4EmilssonMBerndtssonILötvallJMillqvistELundgrenJJohanssonÅThe influence of personality traits and beliefs about medicines on adherence to asthma treatmentPrim Care Respir J20112014114721311839 </plain></SENT>
</text></ref><ref id="b5"><text><SENT sid="323" pm="."><plain>5GuestJFDavieAMRuizFJGreenerMJSwitching asthma patients to a once-daily inhaled steroid improves compliance and reduces healthcare costsPrim Care Respir J200514889816701704 </plain></SENT>
</text></ref><ref id="b6"><text><SENT sid="324" pm="."><plain>6PriceDRobertsonABullenKRandCHorneRStaudingerHImproved adherence with once-daily versus twice-daily dosing of mometasone furoate administered via a dry powder inhaler: a randomized open-label studyBMC Pulm Med201010120051135 </plain></SENT>
</text></ref><ref id="b7"><text><SENT sid="325" pm="."><plain>7CochraneGMHorneRChanezPCompliance in asthmaRespir Med19999376376910603624 </plain></SENT>
</text></ref><ref id="b8"><text><SENT sid="326" pm="."><plain>8BiggadikeKBledsoeRKHassellAMKirkBEMcLayIMShewchukLMX-ray crystal structure of the novel enhanced-affinity glucocorticoid agonist fluticasone furoate in the glucocorticoid receptor-ligand binding domainJ Med Chem2008513349335218522385 </plain></SENT>
</text></ref><ref id="b9"><text><SENT sid="327" pm="."><plain>9RossiosCToYItoMBarnesPJAdcockIMJohnsonMLong-acting fluticasone furoate has a superior pharmacological profile to fluticasone propionate in human respiratory cellsEur J Pharmacol201167024425121920359 </plain></SENT>
</text></ref><ref id="b10"><text><SENT sid="328" pm="."><plain>10BatemanEDBleeckerERLötvallJWoodcockAForthRMedleyHDose effect of once-daily fluticasone furoate in persistent asthma: a randomized trialRespir Med201210664265022342538 </plain></SENT>
</text></ref><ref id="b11"><text><SENT sid="329" pm="."><plain>11BusseWWBleeckerERBatemanEDLötvallJForthRDavisAMFluticasone furoate demonstrates efficacy in patients with asthma symptomatic on medium doses of inhaled corticosteroid therapy: an 8-week, randomised, placebo-controlled trialThorax201267354121828231 </plain></SENT>
</text></ref><ref id="b12"><text><SENT sid="330" pm="."><plain>12BleeckerERBatemanEDBusseWWWoodcockAFrithLHouseKWOnce-daily fluticasone furoate is efficacious in patients with symptomatic asthma on low-dose inhaled corticosteroidsAnn Allergy Asthma Immunol201210935335823062392 </plain></SENT>
</text></ref><ref id="b13"><text><SENT sid="331" pm="."><plain>13BusseWWBatemanEDBleeckerERLötvallJWoodcockAForthRFluticasone furoate (FF), a once-daily inhaled corticosteroid (ICS), is efficacious in patients with uncontrolled asthma across a range of treatment stepsAm J Respir Crit Care Med2011183A1298 </plain></SENT>
</text></ref><ref id="b14"><text><SENT sid="332" pm="."><plain>14BusseWWBatemanEDO'ByrnePMLötvallJWoodcockAMedleyHEfficacy and safety of once-daily (OD) fluticasone furoate (FF) 50 mcg over 24 weeks in adults and adolescents with persistent asthmaEur Respir J201342Suppl. </plain></SENT>
<SENT sid="333" pm="."><plain>57696s </plain></SENT>
</text></ref><ref id="b15"><text><SENT sid="334" pm="."><plain>15National Institutes for Health (NIH)Guidelines for the diagnosis and management of asthma – expert panel report 3 2007. </plain></SENT>
<SENT sid="335" pm="."><plain>Available at: <ext-link ext-link-type="uri" xlink:href="http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.pdf">http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.pdf</ext-link>. </plain></SENT>
<SENT sid="336" pm="."><plain>Last accessed 11 April 2014 </plain></SENT>
</text></ref><ref id="b16"><text><SENT sid="337" pm="."><plain>16WMA Declaration of Helsinki – Ethical Principles for Medical Research Involving Human Subjects. </plain></SENT>
<SENT sid="338" pm="."><plain>Adopted by the 18th WMA General Assembly, Helsinki, Finland, June 1964 and amended (latest) by the 59th WMA General Assembly, Seoul, Korea, October 2008. </plain></SENT>
<SENT sid="339" pm="."><plain>Available at: <ext-link ext-link-type="uri" xlink:href="http://www.wma.net/en/30publications/10policies/b3/index.html">http://www.wma.net/en/30publications/10policies/b3/index.html</ext-link>. </plain></SENT>
<SENT sid="340" pm="."><plain>Last updated October 2008. </plain></SENT>
<SENT sid="341" pm="."><plain>Last accessed 11 April 2014 </plain></SENT>
</text></ref><ref id="b17"><text><SENT sid="342" pm="."><plain>17International Conference on Harmonisation Tripartite Guideline: Guidance for Good Clinical Practice E6 (R1). </plain></SENT>
<SENT sid="343" pm="."><plain>Available at: <ext-link ext-link-type="uri" xlink:href="http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6_R1/Step4/E6_R1__Guideline.pdf">http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6_R1/Step4/E6_R1__Guideline.pdf</ext-link>. </plain></SENT>
<SENT sid="344" pm="."><plain>1996. </plain></SENT>
<SENT sid="345" pm="."><plain>Last accessed 11 April 2014 </plain></SENT>
</text></ref><ref id="b18"><text><SENT sid="346" pm="."><plain>18O'ByrnePMWoodcockABleeckerERBatemanEDLötvallJForthREfficacy and safety of once-daily fluticasone furoate (FF) 50 mcg in adults with persistent asthmaAm J Respir Crit Care Med2013187A2610 </plain></SENT>
</text></ref><ref id="b19"><text><SENT sid="347" pm="."><plain>19BouletLPTurcotteHPrincePLemièreCOlivensteinRLapriseCBenefits of low-dose inhaled fluticasone on airway response and inflammation in mild asthmaRespir Med20091031554156319692221 </plain></SENT>
</text></ref><ref id="b20"><text><SENT sid="348" pm="."><plain>20KellyEAHoutmanJJJarjourNNInflammatory changes associated with circadian variation in pulmonary function in subjects with mild asthmaClin Exp Allergy20043422723314987302 </plain></SENT>
</text></ref><ref id="b21"><text><SENT sid="349" pm="."><plain>21LötvallJBleeckerERBusseWWO'ByrnePMWoodcockAKerwinEMEfficacy and safety of fluticasone furoate 100 μg once-daily in patients with persistent asthma: a 24-week placebo and active-controlled randomised trialRespir Med2014108414924295556 </plain></SENT>
</text></ref><ref id="b22"><text><SENT sid="350" pm="."><plain>22O'ByrnePMBleeckerERBatemanEDBusseWWWoodcockAForthROnce-daily fluticasone furoate alone or combined with vilanterol in persistent asthmaEur Respir J20144377378224136330 </plain></SENT>
</text></ref><ref id="b23"><text><SENT sid="351" pm="."><plain>23AggarwalANGuptaDJindalSKThe relationship between FEV1 and peak expiratory flow in patients with airways obstruction is poorChest20061301454146117099024 </plain></SENT>
</text></ref><ref id="b24"><text><SENT sid="352" pm="."><plain>24LlewellinPSawyerGLewisSChengSWeatherallMFitzharrisPThe relationship between FEV1 and PEF in the assessment of the severity of airways obstructionRespirology2002733333712421241 </plain></SENT>
</text></ref><ref id="b25"><text><SENT sid="353" pm="."><plain>25SchatzMKosinskiMYarlasASHanlonJWatsonMEJhingranPThe minimally important difference of the Asthma Control TestJ Allergy Clin Immunol200912471972319767070 </plain></SENT>
</text></ref><ref id="b26"><text><SENT sid="354" pm="."><plain>26JuniperEFGuyattGHWillanAGriffithLEDetermining a minimal important change in a disease-specific quality of life questionnaireJ Clin Epidemiol19944781878283197 </plain></SENT>
</text></ref><ref id="b27"><text><SENT sid="355" pm="."><plain>27DahlREngelstätterRTrebas-PietraśEKunaP24-week comparison of low-dose ciclesonide and fluticasone propionate in mild to moderate asthmaRespir Med20101041121113020430601 </plain></SENT>
</text></ref></ref-list></SecTag><SecTag type="SUPPL"><sec sec-type="supplementary-material"><title>Supporting Information</title><p>Additional Supporting Information may be found in the online version of this article:</p><supplementary-material content-type="local-data" id="sd1"><label>Appendix S1</label><caption><p><text><SENT sid="356" pm="."><plain>Exclusion criteria at screening and randomization. </plain></SENT>
</text></p><p><text><SENT sid="357" pm="."><plain>Appendix S2. Restricted concomitant medications. </plain></SENT>
</text></p><p><text><SENT sid="358" pm="."><plain>Appendix S3. Details of statistical analyses used for the ‘other’ endpoints. </plain></SENT>
</text></p><p><text><SENT sid="359" pm="."><plain>Appendix S4. Use of concomitant medications during the study treatment period. </plain></SENT>
</text></p><p><text><SENT sid="360" pm="."><plain>Appendix S5. Cumulative incidence curve of time to withdrawal due to lack of efficacy (intent-to-treat population). </plain></SENT>
</text></p></caption><media mimetype="docx" mime-subtype="docx" xlink:href="all0069-1522-sd1.docx" xlink:type="simple" id="d35e2422" position="anchor"/></supplementary-material><supplementary-material content-type="local-data" id="sd2"><label>Figure S1</label><caption><p><text><SENT sid="361" pm="."><plain>Figure related to Appendix S5. </plain></SENT>
<SENT sid="362" pm="."><plain>BD, twice-daily; FF, fluticasone furoate; FP, fluticasone propionate; OD, once daily. </plain></SENT>
</text></p></caption><media mimetype="tif" mime-subtype="tif" xlink:href="all0069-1522-sd2.tif" xlink:type="simple" id="d35e2429" position="anchor"/></supplementary-material></sec></SecTag></back></article>
